These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 15592062

  • 41. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M, Ulusoy E, Cayan S, Akbay E, Görür S, Akbay E.
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [Abstract] [Full Text] [Related]

  • 42. alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
    Paick JS, Ku JH, Shin JW, Yang JH, Kim SW.
    BJU Int; 2006 May; 97(5):1017-23. PubMed ID: 16643483
    [Abstract] [Full Text] [Related]

  • 43. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P, Evans CP, Moon T.
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [Abstract] [Full Text] [Related]

  • 44. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones.
    Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P.
    Urology; 2009 Apr; 73(4):706-9. PubMed ID: 19193417
    [Abstract] [Full Text] [Related]

  • 45. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 46. Brachytherapy-related dysuria.
    Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH.
    BJU Int; 2005 Mar; 95(4):597-602. PubMed ID: 15705087
    [Abstract] [Full Text] [Related]

  • 47. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
    Rosario DJ, Phillips JT, Chapple CR.
    J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
    [Abstract] [Full Text] [Related]

  • 48. Effect of naftopidil on nocturia after failure of tamsulosin.
    Oh-oka H.
    Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
    [Abstract] [Full Text] [Related]

  • 49. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM, Abrams P, Schumacher H, de la Rosette JJ, Michel MC.
    Neurourol Urodyn; 2008 Nov; 27(3):226-30. PubMed ID: 17638312
    [Abstract] [Full Text] [Related]

  • 50. Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
    Ku JH, Um JM, Shin JW, Yang JH, Paick JS.
    Urology; 2006 May; 67(5):978-83. PubMed ID: 16698358
    [Abstract] [Full Text] [Related]

  • 51. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women.
    Pummangura N, Kochakarn W.
    Asian J Surg; 2007 Apr; 30(2):131-7. PubMed ID: 17475584
    [Abstract] [Full Text] [Related]

  • 52. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, Okayama Urological Research Group.
    Scand J Urol Nephrol; 2009 Apr; 43(4):307-14. PubMed ID: 19396723
    [Abstract] [Full Text] [Related]

  • 53. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA, MICTUS Study Group.
    Prostate Cancer Prostatic Dis; 2003 Apr; 6(4):315-23. PubMed ID: 14663474
    [Abstract] [Full Text] [Related]

  • 54. A second cycle of tamsulosin in patients with distal ureteric stones: a prospective randomized trial.
    Porpiglia F, Fiori C, Ghignone G, Vaccino D, Billia M, Morra I, Ragni F, Scarpa RM.
    BJU Int; 2009 Jun; 103(12):1700-3. PubMed ID: 19159408
    [Abstract] [Full Text] [Related]

  • 55. Tamsulosin: the United States trials.
    Narayan P.
    Geriatrics; 1998 Oct; 53 Suppl 2():S29-32. PubMed ID: 9789483
    [Abstract] [Full Text] [Related]

  • 56. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT, Ramsdell J, Ranhosky A, Davidai G, Ruoff G.
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [Abstract] [Full Text] [Related]

  • 57. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
    Lucas MG, Stephenson TP, Nargund V.
    BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
    [Abstract] [Full Text] [Related]

  • 58. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ, MacDonald R, Nelson D.
    J Urol; 2002 Jan; 167(1):177-83. PubMed ID: 11743300
    [Abstract] [Full Text] [Related]

  • 59. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H, Li HZ, Yang Y, Huang ZM, Li YQ, Zhao XF.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 19; 87(23):1590-3. PubMed ID: 17803845
    [Abstract] [Full Text] [Related]

  • 60. α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective randomized study.
    Minardi D, Pellegrinelli F, Conti A, Fontana D, Mattia M, Milanese G, Muzzonigro G.
    Int J Urol; 2015 Jan 19; 22(1):115-21. PubMed ID: 25141907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.